7MM 糖尿病数位治疗市场 - 2025 年至 2033 年

7MM 糖尿病数位疗法市场规模在 2024 年达到 9.6109 亿美元，预计到 2033 年将达到 25.7846 亿美元，在 2025-2033 年预测期内的复合年增长率为 11.7%。

糖尿病的数位疗法是指基于证据的、软体驱动的干预措施，旨在透过数位平台管理和治疗糖尿病。这些治疗方法使用行动应用程式、穿戴式装置和基于云端的系统等先进技术来提供个人化的即时治疗策略和行为介入。目标是利用数据驱动的洞察力来改善糖尿病管理、提高患者治疗效果并预防併发症。

糖尿病的数位疗法使用来自穿戴式装置（例如，连续血糖监测仪）和使用者输入（例如，饮食和运动）的即时资料来提供个人化建议。这有助于患者对药物、饮食和体力活动做出明智的决定，从而优化他们的血糖水平和整体健康状况。

市场动态：

驱动因素与约束因素

不断进步的技术正在推动 7MM 糖尿病数位疗法市场的成长

人工智慧（AI）功能正在融入数位疗法，以即时分析大量患者资料（例如血糖水平、活动、饮食），以了解糖尿病和相关慢性病。这使得制定高度个人化的治疗计划以适应个人的特定需求成为可能，从而改善血糖控制和长期健康结果。因此，主要市场参与者正专注于糖尿病数位治疗中的先进人工智慧功能。

例如，2025 年 2 月，家庭护理领域的领导者、Owens & Minor 家族旗下的 Byram Healthcare 推出了由 Welldoc App 提供支援的个人化数位健康计划 ByramConnect。该程式利用 Welldoc App 先进的人工智慧功能，分析会员六个健康维度的资料，帮助优化 1 型或 2 型糖尿病患者以及高血压、体重管理和心血管风险等相关慢性病患者的治疗效果，为 Byram 会员提供可与其服务提供者和护理团队共享的可行见解和报告。

穿戴式设备，例如连续血糖监测仪（CGM），可即时且连续地追踪血糖值。这有助于更好地决策并及时干预，以防止低血糖或高血糖。与数位治疗平台整合的 CGM 系统为患者和医疗保健提供者提供持续的回馈。这种整合提高了管理效率，减少了紧急干预，并提高了患者的生活品质。这些先进的 CGM 系统采用了小​​型感测器和智慧发射器等技术，成为市场成长的主要趋势。

例如，2024 年 10 月，Ascensia Diabetes Care 为美国糖尿病患者推出了 Eversense 365 连续血糖监测 (CGM) 系统，这是世界上唯一一款为期一年的 CGM。 Eversense 365 由 Senseonics Holdings, Inc. 开发，是唯一一款提供一年准确监测且干扰最小的 CGM，仅需一个 CGM 即可做出自信的决策、长期的安心并提高生活品质。 Senseonics 的 CGM 系统 Eversense 365 包括一个完全插入皮下的小型感测器，可与感测器上佩戴的智慧发射器进行通讯。血糖资料每 5 分钟自动发送到用户智慧型手机上的行动应用程式。

数据隐私和安​​全问题阻碍了糖尿病市场数位疗法的发展

数位治疗平台收集大量敏感的个人健康资料。如果患者不确定这些数据的储存安全性或谁可以存取这些数据，他们通常不愿意共享这些资料。这种犹豫可能会延迟或限制数位健康解决方案的采用。数位治疗平台必须遵守严格的法规，例如美国的《健康保险流通与责任法案》（HIPAA）、欧盟的《一般资料保护规范》（GDPR）以及其他地区的类似法规。处理患者资料的复杂合规性要求可能会成为市场成长的重大障碍，尤其是对于较小的公司或新创公司而言。

数位治疗领域缺乏资料保护和安全的通用标准。不同公司、应用程式和设备之间不一致的做法可能会留下漏洞，从而暴露患者资讯。网路安全风险是一个主要问题，尤其是随着数位健康平台和穿戴式装置的互联程度越来越高。针对健康资料的骇客可能会危害患者的安全和对数位治疗的信任。

例如，根据《HIPAA杂誌》报导，2023 年 8 月，有 2,300 万份医疗记录被洩露。在过去的 12 个月中，平均每月有 9,989,003 份医疗记录被洩露。截至 2024 年 8 月 31 日的一年中，已发生 491 起涉及 500 笔或更多记录的资料外洩事件，已知外洩记录至少有 58,668,002 则。 2024 年的平均洩漏记录规模目前为 119,487 笔记录，中位洩漏记录规模为 4,109 笔记录。

目录

第一章：市场介绍和范围

• 报告目标
• 报告范围和定义
• 报告范围

第 2 章：高阶主管见解与关键要点

• 市场亮点和战略要点
• 主要趋势和未来预测
• 按产品类型分类的片段
• 按应用程式截取的程式码片段
• 最终用户的程式码片段
• 国家摘要

第 3 章：动态

• 影响因素
  • 驱动程式
    • 糖尿病盛行率上升
    • 不断进步的技术
  • 限制
    • 资料隐私和安全问题
    • 监管挑战
  • 机会
    • 糖尿病数位治疗中的人工智慧
  • 影响分析

第四章：战略洞察与产业展望

• 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大销售品牌的成熟领导者
  • 拥有成熟产品的市场领导者
• 新兴创业公司和关键创新者
• CXO 观点
• 最新进展与突破
• 案例研究/正在进行的研究
• 监管和报销情况
  • 我们
  • 法国
  • 德国
  • 义大利
  • 西班牙
  • 英国
  • 日本
• 波特五力分析
• 供应链分析
• 专利分析
• SWOT 分析
• 未满足的需求和差距
• 市场进入和扩张的推荐策略
• 情境分析：最佳情况、基本情况和最坏情况预测
• 定价分析和价格动态

第 5 章：糖尿病数位治疗市场（依产品类型）

• 软体解决方案
  • 行动应用程式
  • 基于 Web 的解决方案
• 硬体解决方案
  • 穿戴式装置
  • 连续血糖监测仪
  • 其他的

第 6 章：糖尿病数位治疗市场（按应用）

• 1 型糖尿病
• 2 型糖尿病
• 糖尿病前期

第 7 章：糖尿病数位治疗市场（以最终用户划分）

• 医院
• 专科诊所
• 家庭护理设置
• 其他的

第 8 章：糖尿病数位治疗市场（按国家/地区划分）

• 我们
  • 关键国家特定动态
• 法国
• 德国
• 义大利
• 西班牙
• 英国
• 日本

第九章：竞争格局与市场定位

• 竞争概况和主要市场参与者
• 市占率分析与定位矩阵
• 策略伙伴关係、併购
• 产品组合和创新的关键发展
• 公司基准化分析

第十章：公司简介

• Welldoc, Inc.
• 公司概况
• 产品组合
  • 产品描述
  • 产品关键绩效指标 (KPI)
  • 历史和预测产品销售量
  • 产品销售量
• 财务概览
  • 公司收入
  • 地区收入份额
  • 收入预测
• 关键进展
  • 合併与收购
  • 关键产品开发活动
  • 监管部门批准等
• SWOT 分析
• Omada Health Inc.
• Glooko, Inc.
• Azumio Inc.
• Abbott Laboratories
• mySugr GmbH
• Dexcom, Inc.
• Health2Sync
• iHealth Labs Inc.
• Medtronic plc

第 11 章：假设与研究方法

• 资料收集方法
• 数据三角测量
• 预测技术
• 数据验证和确认

第 12 章：附录

The 7MM digital therapeutics for diabetes market size reached US$ 961.09 million in 2024 and is expected to reach US$ 2,578.46 million by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033.

Digital therapeutics for diabetes refer to evidence-based, software-driven interventions designed to manage and treat diabetes through digital platforms. These therapeutics use advanced technologies like mobile apps, wearable devices, and cloud-based systems to deliver personalized, real-time treatment strategies and behavioral interventions. The goal is to improve diabetes management, enhance patient outcomes, and prevent complications by leveraging data-driven insights.

Digital therapeutics for diabetes use real-time data from wearables (e.g., continuous glucose monitors) and user inputs (e.g., diet and exercise) to provide personalized recommendations. This helps patients make informed decisions about medication, diet, and physical activity, optimizing their blood glucose levels and overall health.

Market Dynamics: Drivers & Restraints

Rising technological advancements are driving the 7MM digital therapeutics for diabetes market growth

Artificial intelligence (AI) capabilities are being integrated into digital therapeutics to analyze vast amounts of patient data (e.g., glucose levels, activity, diet) in real-time for diabetes and associated chronic conditions. This enables the creation of highly personalized treatment plans that adapt to the individual's specific needs, improving glycemic control and long-term health outcomes. Thus, the key market players are focusing on the advanced artificial intelligence capabilities in their diabetes digital therapeutics.

For instance, in February 2025, Byram Healthcare, a leader in home-based care and part of the Owens & Minor family, launched ByramConnect, a personalized digital health program powered by the Welldoc App. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or type 2 diabetes and associated chronic conditions such as hypertension, weight management, and cardiovascular risk, providing Byram members with actionable insights and reports that can be shared with their providers and care teams.

Wearable devices, such as Continuous Glucose Monitors (CGMs), provide real-time, continuous tracking of glucose levels. This allows for better decision-making and timely interventions to prevent hypoglycemia or hyperglycemia. CGM systems that integrate with digital therapeutics platforms, provide continuous feedback to both patients and healthcare providers. This integration improves management efficiency, reduces emergency interventions, and enhances patient quality of life. These advanced CGM systems with advancements such as small sensors and smart transmitters becoming a key trend for market growth.

For instance, in October 2024, Ascensia Diabetes Care, launched the Eversense 365 continuous glucose monitoring (CGM) system, the world's only One-year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. Senseonics' CGM system Eversense 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Data privacy and security concerns hamper the growth of digital therapeutics for the diabetes market

Digital therapeutics platforms collect vast amounts of sensitive personal health data. Patients are often reluctant to share this data if they are unsure about how securely it is stored or who can access it. This hesitation can delay or limit the adoption of digital health solutions. Digital therapeutics platforms must comply with stringent regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., the General Data Protection Regulation (GDPR) in the EU, and similar regulations in other regions. The complex compliance requirements for handling patient data can be a significant barrier to market growth, especially for smaller companies or startups.

There is a lack of universal standards for data protection and security in the digital therapeutics sector. Inconsistent practices across different companies, apps, and devices can leave vulnerabilities that may expose patient information. Cybersecurity risks are a major concern, especially as digital health platforms and wearable devices become more interconnected. Hackers targeting health data can compromise patient safety and trust in digital therapeutics.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are reported. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records, and the median breach size is 4,109 records.

Segment Analysis

The 7MM digital therapeutics for diabetes market is segmented based on product type, application, end-user, and country.

Product Type:

The software solutions in the product type segment are expected to dominate the 7MM digital therapeutics for diabetes market with the highest market share

Software solutions are highly scalable and can be accessed by a wide range of patients, regardless of location. They can be used on mobile phones, tablets, and computers, making them accessible to a larger population, including those in remote areas. Software solutions allow for the customization of diabetes care based on real-time data, such as blood glucose levels, exercise routines, and dietary habits.

The major market players are continuously focusing on software solutions, which further accelerates the market growth. For instance, in November 2024, Medtronic received U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI was designed to provide real-time insights to users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app, and Medtronic's disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval

Software solutions enable continuous tracking of vital metrics like blood glucose levels, insulin usage and physical activity. This constant monitoring allows for immediate interventions and reduces the need for frequent in-person visits, thus enhancing patient engagement and improving long-term outcomes.

Competitive Landscape

The major players in the 7MM digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The 7MM digital therapeutics for diabetes market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User
• 2.6. Snippet by Country

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Prevalence of Diabetes
    • 3.1.1.2. Rising Technological Advancements
  • 3.1.2. Restraints
    • 3.1.2.1. Data Privacy and Security Concerns
    • 3.1.2.2. Regulatory Challenges
  • 3.1.3. Opportunity
    • 3.1.3.1. Artificial Intelligence in Diabetes Digital Therapeutics
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Emerging Startups and Key Innovators
• 4.3. CXO Perspectives
• 4.4. Latest Developments and Breakthroughs
• 4.5. Case Studies/Ongoing Research
• 4.6. Regulatory and Reimbursement Landscape
  • 4.6.1. US
  • 4.6.2. France
  • 4.6.3. Germany
  • 4.6.4. Italy
  • 4.6.5. Spain
  • 4.6.6. UK
  • 4.6.7. Japan
• 4.7. Porter's Five Force Analysis
• 4.8. Supply Chain Analysis
• 4.9. Patent Analysis
• 4.10. SWOT Analysis
• 4.11. Unmet Needs and Gaps
• 4.12. Recommended Strategies for Market Entry and Expansion
• 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.14. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Software Solutions*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Mobile Apps
  • 5.2.4. Web-Based Solutions
• 5.3. Hardware Solutions
  • 5.3.1. Wearable Devices
  • 5.3.2. Continuous Glucose Monitors
  • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Type-1 Diabetes*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Type-2 Diabetes
• 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Homecare Settings
• 7.5. Others

8. Digital Therapeutics for Diabetes Market, By Country

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 8.1.2. Market Attractiveness Index, By Country
• 8.2. US*
  • 8.2.1. Introduction
  • 8.2.2. Key Country-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
• 8.3. France
• 8.4. Germany
• 8.5. Italy
• 8.6. Spain
• 8.7. UK
• 8.8. Japan

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Welldoc, Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Omada Health Inc.
• 10.3. Glooko, Inc.
• 10.4. Azumio Inc.
• 10.5. Abbott Laboratories
• 10.6. mySugr GmbH
• 10.7. Dexcom, Inc.
• 10.8. Health2Sync
• 10.9. iHealth Labs Inc.
• 10.10. Medtronic plc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us